Cisapride (Propulsid)

A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)

Also Known As:

Networked: 639 relevant articles (131 outcomes, 161 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Augood, C: 4 articles (01/2003 - 01/2000)
2.	Logan, S: 4 articles (01/2003 - 01/2000)
3.	MacLennan, S: 4 articles (01/2003 - 01/2000)
4.	Omura, Satoshi: 3 articles (07/2008 - 08/2007)
5.	Takanashi, Hisanori: 3 articles (07/2008 - 08/2007)
6.	Itoh, Zen: 3 articles (07/2008 - 08/2007)
7.	Gilbert, R: 3 articles (01/2003 - 01/2000)
8.	Talley, N J: 3 articles (09/2002 - 03/2001)
9.	Benatar, A: 3 articles (07/2001 - 12/2000)
10.	Vandenplas, Y: 3 articles (07/2001 - 12/2000)

Related Diseases

1.	Dyspepsia (Indigestion) 05/01/1994 - "At the end of cisapride treatment, the most frequently reported symptoms of functional dyspepsia were significantly improved. " 04/01/1995 - "We were unable to show major differences in the short-term efficacy of cisapride and placebo in functional dyspepsia. " 01/01/1993 - "A double-blind, placebo-controlled trial was performed to determine the therapeutic efficacy of cisapride in patients with refractory functional dyspepsia. " 01/01/1989 - "Chronic idiopathic dyspepsia Cisapride has been shown to be effective in both improving symptoms and also delayed gastric emptying in a six week study. " 06/01/1995 - "Cisapride is also effective in improving symptoms in patients with functional dyspepsia. "
2.	Gastroesophageal Reflux (GERD) 04/01/1993 - "Thus, oral cisapride when taken for 12 weeks promoted healing of oesophagitis and improved symptoms in patients with GERD; although an increase in lower oesophageal sphincter pressure was observed and a reduction in acid reflux was measured, no significant decrease of acid exposure was seen." 06/01/1987 - "A small but significant reduction in the duration of gastro-oesophageal reflux followed cisapride therapy when compared with placebo." 09/01/1997 - "In the acute management of GERD, cisapride is superior to placebo and has the same efficacy as H2 receptor antagonists (H2RAs) in several clinical trials. " 08/01/1998 - "Cisapride, a prokinetic agent, has been reported effective for treating mild-to-moderate grade gastroesophageal reflux disease. " 06/01/1998 - "Cisapride is a prokinetic agent that facilitates gastrointestinal motility and is widely used for the treatment of gastroesophageal reflux disease (GERD) in adults and children. "
3.	Gastroparesis 07/01/1997 - "Thus long-term cisapride therapy at the study dose produced long-term symptomatic improvement in 42% of patients with severe gastroparesis, with sustained acceleration of gastric emptying for up to 2 years." 05/01/1991 - "We conclude that during a 12-month open trial, cisapride was effective in improving gastric emptying in patients with gastric stasis and consistently improved symptoms in those with gastroparesis." 01/01/1989 - "Diabetic gastroparesis In a four week study, cisapride has been shown to be effective in improving symptoms and solid phase gastric emptying. " 04/10/1995 - "The gastrointestinal prokinetic drug, cisapride, is widely used for the treatment of diabetic gastroparesis and disorders of gastrointestinal motility. " 10/01/1995 - "[Influence on glycemic control of improved diabetic gastroparesis by long-term cisapride therapy]."
4.	Constipation 01/01/1996 - "To establish whether cisapride is beneficial in children with intractable constipation, an open trial was performed. " 08/01/2002 - "We conclude that cisapride is effective in the treatment of constipation in patients with PSS." 01/01/2000 - "Cisapride was effective in the treatment of children with constipation." 01/01/2000 - "To determine whether cisapride is effective in the treatment of children with constipation. " 01/01/1994 - "We conclude that cisapride is effective in the treatment of constipation in idiopathic PD."
5.	Ulcer 01/01/1996 - "The role of gastric mucosal sulphydryls in the ulcer-protecting effects of cisapride." 08/01/1993 - "This finding was confirmed using lifetable analysis, with a 35% reduction (95% confidence intervals 10-59%, p < 0.05) in the proportion of ulcer relapses in patients who had received cisapride compared with those treated with placebo. " 08/01/1993 - "The 12 month crude relapse rates (that underestimate the probability of ulcer recurrence) showed that cisapride was superior to placebo (34% (11/32) relapsed on cisapride v 68% (23/34) on placebo, p = 0.007). " 01/01/1993 - "Cisapride therapy initiated in functional dyspeptic patients resulted in moderate or marked improvement in 79.1% of the patients with the highest response rates for dysmotility-like (85.2%), reflux-like (81.0%), and non-specific dyspepsia (76.1%) (versus 52.0% for ulcer-like dyspepsia)." 03/01/1987 - "Cisapride caused significant improvement compared with placebo with regard to frequency and severity of symptoms and may therefore be useful in the therapy of non-ulcer dyspepsia."

Related Drugs and Biologics

1.	Domperidone (Domperidon)
2.	Metoclopramide (Reglan)
3.	Ranitidine (Zantac)
4.	Omeprazole (Esomeprazole)
5.	Cimetidine (Biomet)
6.	Antral
7.	tegaserod (Zelnorm)
8.	Neostigmine (Neostigmine Bromide)
9.	Glycopyrrolate (Glycopyrronium Bromide)
10.	Simethicone

Related Therapies and Procedures

1.	Enteral Nutrition (Feeding, Tube)
2.	Lithotripsy (Extracorporeal Shockwave Lithotripsy)
3.	Oral Administration
4.	Resuscitation
5.	Aftercare (After-Treatment)